



The Pfizer/BioNTech COVID-19 vaccine is 91.3% effective up to 6 months after the second dose and 100% effective against severe disease as defined by the US Centers for Disease Control and Prevention (CDC), according to updated data today from the phase 3 trial.

The vaccine was also 100% effective at preventing illness among trial participants in South Africa, where the highly transmissible B1351 variant is dominant, the Pfizer [news release](#) said. No safety issues were identified among the more than 44,000 participants 16 years or older over at least 6 months' follow-up after the second shot.

<https://www.cidrap.umn.edu/news-perspective/2021/04/pfizer-covid-vaccine-91-effective-least-6-months>